|
SIGNIFICANT CONCENTRATIONS (Details) (Revenues, Customer concentration)
|
12 Months Ended | |||||
|---|---|---|---|---|---|---|
|
Dec. 31, 2012
AstraZeneca
|
Dec. 31, 2010
AstraZeneca
|
Dec. 31, 2012
Daiichi
|
Dec. 31, 2012
BerGenBio
|
Dec. 31, 2011
BerGenBio
|
Dec. 31, 2011
Merck Serono
|
|
| SIGNIFICANT CONCENTRATIONS | ||||||
| Concentration risk as a percentage of revenue | 44.00% | 100.00% | 33.00% | 22.00% | 11.00% | 89.00% |
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|